IL-37 (human) ELISA Kit

Serum Interleukin-37 Concentrations and HBeAg Seroconversion in Chronic HBV Patients During Telbivudine Treatment: C. Li, et al.; J. Interferon Cytokine Res. 33, 612 (2013)

Elevated levels of cerebrospinal fluid and plasma interleukin-37 in patients with guillain-barré syndrome: C. Li, et al.; Mediators Inflamm. 2013, 639712 (2013)

IL-37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: its correlation with disease activity: L. Ye, et al.; J. Transl. Med. 12, 69 (2014)

Plasma Levels of IL-37 and Correlation with TNF-alpha, IL-17A, and Disease Activity during DMARD Treatment of Rheumatoid Arthritis: P.-W. Zhao, et al.; PLOS One 9, e95346 (2014)

Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis: P. Italiani, et al.; J. Neuroinflamm. 11, 94 (2014)

Elevated plasma IL-37, IL-18, and IL-18BP concentrations in patients with acute coronary syndrome: Q. Ji, et al.; Mediat. Inflamm. 2014, ID165742 (2014)

Interleukin-37 is increased in ankylosing spondylitis patients and associated with disease activity: B. Chen, et al.; J. Transl. Med. 13, 36 (2015)

Interleukin-37 suppresses tumor growth through inhibition of angiogenesis in non-small cell lung cancer: G. Ge, et al.; J. Exp. Clin. Cancer Res. 35, 13 (2016)

Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus: J. Godsell, et al.; Sci. Reports6, 34604 (2016)